Paeon

DGAP-News: PAION AG ANNOUNCES SUCCESSFUL COMPLETION OF CAPITAL INCREASE WITH SUBSCRIPTION RIGHTS

Retrieved on: 
Wednesday, April 7, 2021
Paion, Paeon

Aachen (Germany), 07 April 2021 - The specialty pharmaceutical company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard) today announces that the Company has successfully completed its rights offering.

Key Points: 
  • Aachen (Germany), 07 April 2021 - The specialty pharmaceutical company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard) today announces that the Company has successfully completed its rights offering.
  • PAION will use the net proceeds from the capital increase to prepare commercial launches for its product portfolio in selected European countries and for general corporate purposes.
  • PAION AG's CEO Dr. Jim Phillips commented: "We appreciate the great interest in the capital increase.
  • PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services.

DGAP-News: PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVO (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM

Retrieved on: 
Wednesday, April 7, 2021
Feminine given names, Given names, Pyridines, Remimazolam, Paion, Paeon, Hana, remimazolam, PAION

Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of ByfavoTM (remimazolam) for the use in general anesthesia in South Korea.

Key Points: 
  • Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of ByfavoTM (remimazolam) for the use in general anesthesia in South Korea.
  • Remimazolam was approved in South Korea for general anesthesia in January 2021 and will be marketed under the brand name ByfavoTM.
  • Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "The launch in South Korea is great news and a testament to the strong commitment of our partner Hana Pharm.
  • PAION is eligible to royalties of 10% of net sales in South Korea.

DGAP-News: ​​​​​​​PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2020

Retrieved on: 
Tuesday, March 30, 2021
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Paion, Sedation, Paeon

Outstanding milestones were the first approvals of remimazolam in key pharma markets and the first successful launches by our partners.

Key Points: 
  • Outstanding milestones were the first approvals of remimazolam in key pharma markets and the first successful launches by our partners.
  • The associated milestone payments have led to a positive full-year result in 2020," commented Dr. Jim Phillips, CEO of PAION AG.
  • In Europe, remimazolam (trade name Byfavo(R)) is approved in procedural sedation and in addition PAION is seeking approval for general anesthesia.
  • In January 2020, PAION and Hana Pharm extended their license agreement for remimazolam to include Southeast Asia (Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam).

DGAP-News: PAION GRANTS EXCLUSIVE LICENSE TO TTY BIOPHARM FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN TAIWAN

Retrieved on: 
Friday, March 5, 2021
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Tty, Paion, Tty, Paeon, remimazolam, TTY Biopharm, PAION

Aachen (Germany), 05 March 2021 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and TTY Biopharm Company Limited ("TTY") today announce that they have entered into a license agreement for remimazolam with PAION granting TTY an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in Taiwan.

Key Points: 
  • Aachen (Germany), 05 March 2021 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and TTY Biopharm Company Limited ("TTY") today announce that they have entered into a license agreement for remimazolam with PAION granting TTY an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in Taiwan.
  • Under the terms of the agreement, TTY has the right and obligation to further develop remimazolam in all indications in Taiwan with PAION's support.
  • Dr. Jim Phillips, CEO of PAION AG, commented: "We are excited to have TTY as our partner for remimazolam in Taiwan.
  • Remimazolam, developed by PAION, has been approved in many countries and is a promising medicine for physicians and patients.

DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA

Retrieved on: 
Wednesday, July 15, 2020
Chemical compounds, Organic compounds, Paion, Remimazolam, Paeon, remimazolam, PAION

Aachen (Germany), 15 July 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that PAION, U.S. remimazolam licensee Cosmo Pharmaceuticals NV ("Cosmo") and Acacia Pharma ("Acacia") have agreed to assign the BYFAVOTM (remimazolam) license agreement signed in 2016 between Cosmo and PAION to Acacia.

Key Points: 
  • Aachen (Germany), 15 July 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that PAION, U.S. remimazolam licensee Cosmo Pharmaceuticals NV ("Cosmo") and Acacia Pharma ("Acacia") have agreed to assign the BYFAVOTM (remimazolam) license agreement signed in 2016 between Cosmo and PAION to Acacia.
  • The terms of the license agreement remain unchanged but will now be between PAION and Acacia, with Cosmo no longer being a party to the agreement.
  • Alessandro Della Ch, CEO of Cosmo, said: "This assignment is important in order to let Acacia entertain a direct relationship with PAION.
  • We look forward to continue to contribute to the success of BYFAVOTM as shareholders of both Acacia and PAION."

DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES

Retrieved on: 
Wednesday, July 8, 2020
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Yorkville, Toronto, Yorkville, Convertible bond, Paion, Sedation, Paeon, Convertible security, remimazolam, PAION

Aachen (Germany), 08 July 2020 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the EUR 5 million convertible notes issued to Yorkville Advisors Global, LP (Yorkville) in September 2019 have been converted into a total of 2,363,350 PAION shares.

Key Points: 
  • Aachen (Germany), 08 July 2020 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the EUR 5 million convertible notes issued to Yorkville Advisors Global, LP (Yorkville) in September 2019 have been converted into a total of 2,363,350 PAION shares.
  • The convertible notes have thus been converted completely and a further use of the financing agreement with Yorkville is not planned.
  • Abdelghani Omari, CFO of PAION AG, commented: "We would like to thank Yorkville for their support over the last year.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.

DGAP-News: PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2019

Retrieved on: 
Thursday, March 26, 2020
European Union, Multilateral development banks, Paion, European Investment Bank, Paeon, Financial services, Banking

Dr. Jim Phillips, CEO of PAION AG, commented: "2019 was a highly productive year for PAION.

Key Points: 
  • Dr. Jim Phillips, CEO of PAION AG, commented: "2019 was a highly productive year for PAION.
  • In 2016, PAION entered into a U.S. license agreement for remimazolam with Cosmo which remains unchanged.
  • In June 2019, PAION and the European Investment Bank (EIB) signed a loan agreement for up to EUR 20 million.
  • On 16 October 2019, Dr. James (Jim) Phillips joined PAION AG as the new Chief Executive Officer (CEO).